Analysis of Chemotherapy Regimens on Survival Rate of Breast Cancer Patients

Abstract

Breast cancer in Indonesia is among the first with the highest number of new cancer cases with the second mortality in cancer after lung cancer in 2020. Anthracycline-taxane based regimens and taxane-based regimens are often breast cancer chemotherapy modalities that can support increased patient survival. Side effects occur more frequently in combination regimens. The selection of the right regimen is expected to support the improvement of patient survival. This study aims to analyze the survival rate of chemotherapy regimen groups and hazard ratio factors that are thought to affect survival in breast cancer patients. This study used an observational and retrospective cohort method. The statistical analyzes used in this study include Kaplan-Meier analysis to measure survival rates, Log-rank test to observe the differences between regimen groups and Cox proportional hazards regression to analyze factors that influence survival. Patients who were included in the inclusion and exclusion criteria were 71 patients, consisting of 47 patients who received anthracycline-taxane based combination and 24 patients who received taxane-based chemotherapy. The percentage of one-year and two-year survival in the anthracycline-taxane based combination was 93.6% and taxane-based 83.3% (p>0.05). Multivariate analysis showed that stage increased risk 9 times based on hazard ratio values obtained from cox regression tests (HR 9.60; 95% CI 1.60-57.54; p<0.05). Another significant factor in the multivariate analysis was that delaying chemotherapy increased the risk of survival 5 times (HR 5,58; CI 95% 1.12-27.85 ; p<0.05). Based on research, it can be concluded that anthracycline-taxane based and taxane based combination regimens can be used as a treatment modality for breast cancer patients in both early and advanced stages.